Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome
Conditions: Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia in Remission; Acute Myeloid Leukemia; Acute Myeloid Leukemia in Remission; Hematopoietic Cell Transplantation Recipient; Minimal Residual Disease; Myelodysplastic Syndrome; Secondary Acute Myeloid Leukemia Interventions: Drug: Fludarabine; Other: Laboratory Biomarker Analysis; Drug: Melphalan; Radiation: Total Marrow Irradiation Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Cancer & Oncology | Leukemia | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Transplants